Cell analysis instrumentation and solutions provider Cytek Biosciences (Fremont, CA) has closed a $120 million Series D funding round, co-led by RA Capital and Hillhouse Capital, with OrbiMed and LYFE Capital also participating. The investment will be used to expand the company’s global infrastructure, sustain its growing momentum, and enable it to deliver on its flow cytometry technology platform.
Cytek’s cell analysis systems contain architectures that detect the full spectrum of the many fluorescent particles labeled on each cell. This technology enables the Cytek Aurora to run beyond 40 color panels, a significant increase in the number of colors per sample, which in turn offers a much more complete picture of all the different cellular players in the immune system. With the recent unveiling of a new family of cFluor reagents, the company is transitioning into a complete solution provider for the cell analysis market—inclusive of clinical diagnostics. The company’s Series D funding round will help accelerate this transition and offer expanded support for key areas of study such as immunotherapy, immuno-oncology, and infectious diseases such as COVID-19.
Additionally, RA Capital and Hillhouse Capital have joined Cytek’s board of directors.
For more information, please visit cytekbio.com.
Source: Cytek Biosciences press release via Globe Newswire – November 5, 2020